MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Evoke Pharma Book Value 2011-2026 | EVOK
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Evoke Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.58 M | 4.08 M | 3.56 M | -3.21 M | 4.38 M | 4.03 M | 2.17 M | 3.79 M | 3.46 M | 9.19 M | 21.2 M | -19.7 M | -17.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | -19.7 M | 979 K |
Quarterly Book Value Evoke Pharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 M | 4.37 M | 5.84 M | 7.04 M | 4.39 M | 2.66 M | 3.5 M | -2.58 M | -874 K | 538 K | 2.13 M | 4.08 M | 5.53 M | 7.19 M | 1.93 M | 3.56 M | 4.77 M | 5.97 M | 7.81 M | -3.21 M | -3.21 M | -3.21 M | -3.21 M | 4.38 M | 4.38 M | 4.38 M | 6.4 M | 4.03 M | 4.05 M | 4.39 M | 4.46 M | 2.17 M | 2.17 M | 2.17 M | 2.17 M | 3.79 M | 3.79 M | 3.79 M | 3.79 M | 3.46 M | 3.46 M | 3.46 M | 3.46 M | 9.19 M | 9.19 M | 9.19 M | 9.19 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | -1.43 M | -1.43 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | -3.21 M | 4.74 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.69 | 1.32 % | $ 1.42 B |  Canada |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.25 | -3.02 % | $ 134 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.74 | 0.29 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 4.17 | -1.07 % | $ 549 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 12.94 | -3.14 % | $ 663 M | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.52 | 0.19 % | $ 2.05 B |  France |
 |
Sundial Growers
SNDL
|
1.13 B | $ 1.65 | 0.3 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.65 | -3.44 % | $ 4.53 M | USA |
 |
Evolus
EOLS
|
5.52 M | $ 5.61 | -2.35 % | $ 348 M | USA |
 |
Harrow Health
HROW
|
70.4 M | $ 47.21 | -7.51 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 1.29 | -4.79 % | $ 22.5 M |  China |
 |
Tilray
TLRY
|
3.33 B | $ 9.15 | 0.26 % | $ 5.65 B | Canada |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
-82 M | $ 7.47 | -3.93 % | $ 2.73 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 4.78 | -1.04 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
32.3 M | $ 2.35 | 1.73 % | $ 317 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 4.25 | -0.47 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.67 | -9.03 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
4.32 B | $ 14.99 | 1.94 % | $ 2.06 B | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 1.08 | -0.46 % | $ 4.66 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 0.94 | -3.6 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.27 | -3.61 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
138 M | $ 9.12 | -2.04 % | $ 648 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
137 M | $ 5.25 | -1.22 % | $ 214 M | USA |
 |
SCYNEXIS
SCYX
|
73 M | $ 0.67 | 0.42 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.09 | 1.46 % | $ 21.8 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 12.74 | 1.07 % | $ 15.4 B | USA |
 |
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M | USA |